ADC Technology

Changing the Future of Cancer Treatment through Genetic Engineering-Clay Siegall

Most patients who suffer from cancer succumb not because of the cancer itself but because of the harshness of the chemotherapy. Clay Siegall had this kind of experience when he was young after his father was diagnosed with cancer. His father struggled with the sickness for four years before he succumbed due to the harshness of the therapy. This is one of the events which really shaped Clay Siegall’s future plans. He enrolled for a degree program in zoology and later specialized in Genetics at the post graduate level.

Clay worked for a number of firms as a lab technician before he left to set up Seattle Genetics in 1998. Seattle Genetics was set up as part of a plan to create ADCs, antibody drug conjugates. For the past two decades, they have been trying to come up with ADCs which can combat different types of lymphomas. The first of the drug to be approved by the FDA was Adcetris, which was approved in 2015. Since its approval, the drug has received overwhelming sales all over the world with more than 75 countries endorsing it. In Canada, there was a time when Takeda Pharmaceuticals was marketing it. Seattle Genetics has since started retailing their drugs.

Clay Siegall has been at the helm in Seattle Genetics at a time when a lot of positive change has been happening. For instance, he has bargained for partnerships with big pharma such as GlaxoSmithKline, Pfizer, Genentech and Daiichi Sankyo. The partnerships are meant to get the company the financing that they need to carry out their research and their clinical trials.

So far, the company has held a vast number of trials for different drugs. These include Hodgkin Lymphoma, Multiple Myeloma, Solid Tumors, breast cancer, and Leukemia. The company plans to expand their capacity even further so that they can intensify their research.

Seattle Genetics has been listed on NASDAQ since 2001. They are listed under the name SGEN, and their shares have been doing very well. When asked whether the company is planning to sell off to big pharma any time, Clay Siegall says that while it is common for successful startups to sell off, he has a solid strategy for the future of Seattle Genetics. He states that his company has gotten to the level of success they are enjoying right now because of dedication and hard work, and is confident that with the same spirit, they will get even more of their ADCs approved for public use.